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Background: The induction of protein synthesis by exogenous delivery of coding synthetic mRNA in desired cells
is an auspicious strategy in the fields of basic cell biology, regenerative medicine, treatment of diseases, and
reprogramming of cells. Here, we produced modified messenger RNA (mRNA) with reduced immune activation
potential and increased stability and performed transfection experiments with different cells, HEK293 cells,
BJ fibroblasts, and endothelial cells (ECs).
Results: The mRNA induced protein expression in cells was analyzed after transfection with different mRNA
amounts and transfection reagents using flow cytometry. Different cell types showed different degrees of eGFP
expression. HEK293 cells exhibited the highest eGFP expression compared to the BJ fibroblasts and ECs. However,
the mRNA induced eGFP expression was detected in all cell types until 3 days after transfection. Already, the use
of 0.5 μg of the synthesized mRNA led to the significant expression of eGFP in ECs. From all analyzed ECs
approximately 87% were eGFP positive, which showed a high transfection efficiency.
Conclusions: The synthesis of stabilized mRNA and the high transfection efficiency will enable the mRNA
engineering of ECs as well as other somatic cells. The delivery of synthetic exogenous mRNA into cells allows the
transient expression of desired proteins, which would be normally not expressed by the cells.
Keywords: mRNA synthesis, Transfection, Protein synthesisBackground
Proper functioning of cells, differentiation and production
of signaling molecules are controlled via translation of mes-
senger RNA (mRNA) into proteins by ribosomes (Figure 1).
Thus, hereditary or acquired genetic disorders followed by
defects of protein expression can lead to serious diseases.
In the last years, the administration of mRNA as a thera-
peutic agent has gained an enormous potential in the fields
of disease treatment [1], regenerative medicine [2-4], and
vaccination [5]. Hitherto, clinical applications of conven-
tional mRNAs were limited due to the low stability and the
strong immunogenicity. However, pioneering work from
Kariko and colleagues demonstrated that the replacement* Correspondence: hans-peter.wendel@med.uni-tuebingen.de
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uridine dramatically abrogate immune activation [6,7].
They also found that pseudouridine modified mRNAs have
a higher translational capacity than unmodified mRNAs
and increased biological stability [8,9].
The ability to produce modified mRNAs allows the pro-
tection of naturally labile mRNA in biological fluids and
greatly minimizes innate immune responses. Kormann
et al. demonstrated that a combination of nucleotide modi-
fications prevents the interaction of synthesized mRNA
with TLR3, TLR7, TLR8, and RIG-1 [1]. Thus, the use of
modified mRNA provides the possibility for controlled and
temporary delivery of desired transcripts in vivo or in vitro
to induce protein expression. Furthermore, in comparison
to the viral gene therapy vectors [10], the risk of oncogen-
esis [11] is prevented due to lack of integration into theral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Synthesis of proteins in the cells. A) Natural pathway. Genetic code of the protein is transcribed into mRNA in the nucleus and
transported to the cytosol. The mRNA is then translated by ribosomes into proteins. B) Synthetic pathway. Synthetically produced mRNA is
transfected into the cells. The mRNA is then translated by ribosomes into proteins.
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mRNA will get better clinical acceptance in the future.
Here, we synthesized modified eGFP mRNA and
transfected different cell types, endothelial cells (ECs), BJ
fibroblasts as well as HEK293 cells, with this mRNA.
Transfection efficiency and mRNA induced eGFP ex-
pression in cells was compared after the transfection
with different amounts of mRNA and different transfec-
tion reagents. Furthermore, the protein expression in
transfected cells was measured up to 3 days after
transfection.
Materials and methods
Production of modified mRNA
Coding DNA sequence (CDS) with known flanking se-
quences was amplified by PCR using specific primers.
PCR product was then purified and the quality of the
generated DNA was determined. Using the in vitro tran-
scription (IVT) process, mRNA was generated from theDNA product. Subsequently, the product was purified
and treated with phosphatase to remove 5′-triphos-
phates. After the additional purification and quality con-
trol of generated mRNA, transfection experiments were
performed.
Consent
ECs were isolated from residual saphenous vein biopsies
of patients who had undergone coronary artery bypass
graft surgery. All patients gave informed consent to par-
ticipate and for the publication of this report. The study
was approved by the Ethical Committee of the Faculty of
Medicine of the University of Tuebingen.
Amplification of plasmid inserts and adding of polyT-tail by
polymerase chain reaction (PCR)
To obtain, the DNA template for the IVT, pcDNA
3.3_eGFP Plasmid (Addgene, cat. no. 26822) containing
CDS of interest, here eGFP, was amplified using PCR.
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TAATACG-3′ and reverse primer 5′- T120-CTTCCTA
CTCAGGCTTTATTCAAAGACCA-3′ for the insert
amplification were purchased from ELLA Biotech
(Martinsried, Germany) in HPLC grade. Thereby, a poly
T-tail of 120 thymidines (T) was added to the insert by
using a reverse primer with a T120 extension. Thus, after
IVT, the generated mRNAs obtained a poly A-tail with a
defined length. PCR reactions of 100 μl were per-
formed using HotStar HiFidelity Polymerase Kit (Qiagen,
Hilden, Germany) and contained 0.7 μM of each forward
and reverse primer, 1× Q-solution, 1× HotStar HiFidelity
PCR buffer, 50 ng plasmid DNA, 2.5 U HotStar HiFide-
lity DNA polymerase. PCR was run using the following
cycling protocol: initial activation step at 95°C for 5 min,
followed by 25 cycles of denaturation at 95°C for 45 s,
annealing at 55°C for 1 min, extension at 72°C for 1 min
and final extension at 72°C for 10 min. PCR reaction
was purified using QIAquick PCR Purification Kit
(Qiagen, Hilden, Germany) according manufacturer’s in-
structions and the DNA was eluted using 20 μl
nuclease-free water. The quality and purity of the DNA
was assessed by 1% agarose gel electrophoresis.
In vitro transcription (IVT)
After the PCR, the genetic information is in vitro tran-
scribed from DNA to mRNA using MEGAscript® T7 Kit
(Life Technologies, Darmstadt, Germany). The generated
mRNA transcript is then used to induce protein expres-
sion in cells. At first, 23 μl NTP/cap analog mixture
containing 7.5 mM ATP, 1.875 mM GTP (both from
MEGAscript® T7 Kit), 7.5 mM Me-CTP, 7.5 mM
Pseudo-UTP (both from TriLink BioTechnologies, San
Diego, USA), and 2.5 mM 3′-O-Me-m7G(5′)ppp(5′)G
RNA cap structure analog (New England Biolabs,
Frankfurt am Main, Germany) was prepared and mixed
thoroughly. The IVT reaction mixture of 40 μl was then
assembled by adding 40 U RiboLock RNase inhibitor
(Thermo Scientific, Waltham, USA), 1 μg PCR product,
1× reaction buffer and 1× T7 RNA polymerase enzyme
mix. The IVT reaction mixture was incubated at 37°C
for 3 h in a thermomixer. To remove the template DNA,
1 μl TURBO DNase (from MEGAscript® T7 Kit) was
added to the IVT reaction mixture and incubated for
15 min at 37°C. Then, the reaction mixture was purified
using RNeasy Mini Kit (Qiagen, Hilden, Germany) ac-
cording to manufacturer’s instructions. The modified
mRNA was eluted from the spin column membrane
twice with 40 μl nuclease-free water.
Treatment of purified mRNA with Antarctic phosphatase
The generated mRNA is treated with Antarctic phosphat-
ase (New England Biolabs, Frankfurt am Main, Germany)
to remove 5′ triphosphates, which can be recognized byRIG-1, and lead to the immune activation. Furthermore,
the phosphatase treatment prevents the recircularization in
a self-ligation reaction. For this purpose, 9 μl of 10× Ant-
arctic phosphatase reaction buffer was added to 79 μl of
purified mRNA solution. Subsequently, 2 μl of Antarctic
phosphatase (5 U/μl) was added to the reaction mixture
and incubated at 37°C for 30 min. The treated mRNA was
purified using RNeasy Mini Kit (Qiagen, Hilden, Germany)
according to manufacturer´s instructions. The modified
mRNA was eluted from the spin column membrane twice
with 50 μl nuclease-free water. The concentration was mea-
sured using ScanDrop spectrophotometer (Analytic Jena,
Jena, Germany). The concentration of mRNA was adjusted
to 100 ng/μl by adding nuclease-free water. The quality and
purity of synthesized modified mRNA was determined by
1% agarose gel electrophoresis. The modified mRNA was
aliquoted and stored at -80°C and used for transfections.
Cultivation of cells
HEK293 cells were cultivated in DMEM with high glu-
cose (PAA Laboratories, Cölbe, Germany) supplemented
with 10% FBS (Life Technologies, Darmstadt, Germany),
2 mM L-glutamine (PAA Laboratories), and 1% penicillin/
streptomycin (PAA Laboratories). BJ human foreskin fibro-
blasts (Stemgent, Cambridge, USA) were cultivated in
DMEM with high glucose containing 10% FBS, 2 mM L-
glutamine, 1% penicillin/streptomycin, and 30 mM HEPES
(Life Technologies, Darmstadt, Germany). Human endo-
thelial cells (ECs) were isolated as described previously [12]
and cultivated in flasks precoated with 0.1% gelatin in
Vasculife® EnGS EC culture medium (CellSystems,
Troisdorf, Germany) containing VascuLife EnGS LifeFac-
tors Kit, 50 mg/ml gentamicin, and 0.05 mg/ml amphoteri-
cin B (PAA Laboratories). Cells were kept at 37°C with 5%
CO2 and media was changed every 3 days. Cells were
passaged using trypsin/EDTA (0.04%/0.03%, PromoCell,
Heidelberg, Germany). BJ fibroblasts at passage 7-9, endo-
thelial cells at passage 3-5 were used for all experiments.
Preparing of cells for mRNA transfection
For performing of transfection experiments, 1.5 × 105
cells were plated per well of 12-well plate. The cells were
incubated overnight at 37°C in a cell incubator. Next
day, transfection experiments were performed.
Detachment of cells and performing of flow cytometry
Using trypsin/EDTA (0.04%/0.03%), cells were detached,
washed, and fixed in 1× CellFix solution (BD Biosci-
ences, Heidelberg, Germany). A total of 10,000 cells was
analyzed by FACScan flow cytometer (Becton Dickinson,
Heidelberg, Germany). Cells expressing eGFP were de-
tected using the FL1 (green) channel and measuring the
fluorescence at 509 nm. FACS data were displayed in
histograms. For the evaluation, a marker M1 was set,
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control cells (cells treated with transfection medium
without mRNA). Using histogram statistics of the Cell-
Quest Pro Software (Becton Dickinson), the percentage
of eGFP positive cells was determined to assess the
transfection efficiency. Geo Mean (geometric mean)
values show the strength of the fluorescence intensity.
Higher Geo Mean values reflect stronger fluorescent in-
tensity, indicating a higher production of eGFP.
Performing of transfections with different transfection
reagents
Expression of eGFP was verified after performing
of transfection with 1.5 μg mRNA, using TransIT mRNA
transfection reagent (Mirus Bio LLC, Madison,
USA), Lipofectamine® 2000 (Life Technologies, Darmstadt,
Germany), or Stemfect RNA transfection reagent
(Stemgent, Cambridge, USA). From each transfection re-
agent 2 μl was used for transfections. The cells were incu-
bated for 4 h with transfection complexes, subsequently the
transfection mixture was replaced by cell culture medium.
The expression of eGFP was measured 24 h after
transfection.
To perform the transfection with Trans-IT-mRNA trans-
fection reagent, 1.5 μg mRNA, 2 μl TransIT-mRNA trans-
fection reagent and 2 μl boost reagent were added to 100 μl
Opti-MEM I reduced serum media (Life Technologies,
Darmstadt, Germany) and incubated for 5 min at room
temperature. Afterwards, transfection complexes were
added for 4 h to 1 ml cell medium in 12 well plates.
Two tubes containing 25 μl Stemfect transfection
buffer were prepared for assembling of the Stemfect
RNA transfection mixture. In the first tube, 2 μl of
Stemfect RNA transfection reagent was added. In the
second tube, 1.5 μg of mRNA was added. Then the
diluted transfection reagent solution was pipetted to
the diluted mRNA solution, mixed, and incubated for
15 minutes at room temperature. The mRNA trans-
fection complex was added for 4 h to 1 ml cell
medium in 12 well plates.
Using the transfection reagent Lipofectamine 2000,
two different transfections were performed. Lipofecta-
mine 2000/mRNA complexes were added to the cell
culture media or given only in Opti-MEM I reduced
serum media to the cells. For transfection of cells
only with Opti-MEM I reduced serum media, the Li-
pofectamine 2000 transfection mixtures were prepared
by addition of 2 μl Lipofectamine 2000 and 1.5 μg
mRNA to 500 μl Opti-MEM I reduced serum media
and incubation for 20 min at room temperature. Cell
culture medium was aspirated, cell layer was washed
with 1 ml DPBS and transfection mixture was given
on adherent growing cells for 4 h at 37°C. This
transfection method is referred to as Lipofectamine2000_optimized. For transfection of cells in cell cul-
ture medium, 2 μl Lipofectamine 2000 and 1.5 μg
mRNA were added to 100 μl Opti-MEM I reduced
serum media and incubated for 5 min at room
temperature. Then, the mixture was added to 1 ml
cell culture medium per well of a 12-well plate for
4 h at 37°C.
Transfection of cells with different Lipofectamine
2000 amounts
To determine the required amount of Lipofectamine
2000 for forming of lipoplexes, different amounts of
Lipofectamine 2000, 1, 2, 4, 6 μl, were used to trans-
fect the cells. For transfection of one well of 12-well
plate, 500 μl Opti-MEM I reduced serum media was
prepared containing 2.5 μg of eGFP mRNA and
respective amount of Lipofectamine 2000. The com-
ponents were gently mixed by pipetting. The transfec-
tion mixture was then incubated at room temperature
for 20 min to generate lipoplexes for transfection.
Cells were washed with 500 μl DPBS/well, the trans-
fection mixture was pipetted into the well. After 4 h
incubation at 37°C and 5% CO2, the transfection mix-
ture was replaced by 1 ml complete cell culture
medium. Cells were cultivated for 24 h in the cell in-
cubator and analyzed using flow cytometry.
Transfection of cells with different mRNA amounts
To determine the required amount of mRNA for induction
of protein expression, different amounts of eGFP mRNA, 0,
0.5, 1, 1.5, 2, 2.5 μg, were used to perform the transfection
of cells. For transfection of one well of 12-well plate, 500 μl
Opti-MEM I reduced serum media with respective amount
of mRNA and 2 μl of Lipofectamine 2000 was prepared.
The components were gently mixed and incubated 20 min
at room temperature. Cells were washed with 500 μl DPBS/
well and the transfection mixture was added. Cells were in-
cubated for 4 h at 37°C and 5% CO2. Afterwards, the trans-
fection mixture was aspirated and 1 ml complete cell
culture medium was added to the cells. Cells were incu-
bated for 24 h in the cell incubator. Using flow cytometry,
the eGFP expression in the cells was verified.
Determination of eGFP expression in mRNA transfected
cells over time
To evaluate the duration of protein expression in
cells, eGFP expression was determined 1, 2, and 3
days after mRNA transfection. Transfection complexes
were generated in 500 μl Opti-MEM I reduced serum
media by adding of 2.5 μg eGFP mRNA and 2 μl Li-
pofectamine 2000. The components were incubated at
room temperature for 20 min to form lipoplexes.
Cells were washed with 500 μl DPBS/well. Subse-
quently, cells were incubated for 4 h at 37°C and 5%
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was aspirated and 1 ml complete cell culture medium
was added to the cells. Cells were cultivated for 1, 2,
and 3 days in the cell incubator and analyzed using
flow cytometry.Figure 2 Transfection of HEK293 cells, BJ fibroblasts, and ECs with 1.5
and modifications.Fluorescence microscopic analysis of eGFP
transfected cells
Using fluorescence microscopy, the expression of eGFP
in HEK293 cells, BJ fibroblasts, and ECs was examined.
The cells were transfected with 1.5 μg eGFP mRNAμg eGFP mRNA using different transfection reagents
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graphs were taken 24 h post-transfection.Statistical analysis
Data are shown as means ± standard deviation (SD). One-
way analysis of variance (ANOVA) for repeated measures
followed by the Bonferroni’s multiple comparison test was
performed to compare the means. All statistical analyses
were performed double-tailed using GraphPad Prism
version 5.01. Differences of p < 0.05 were considered
significant.Results
Performing of mRNA transfection with different
transfection reagents
HEK293 cells, BJ fibroblasts, and ECs were transfected
with 1.5 μg mRNA using TransIT mRNA transfection
reagent, Lipofectamine 2000, or Stemfect RNA transfec-
tion reagent (Figure 2).Figure 3 Transfection of HEK293 cells, BJ fibroblasts, and ECs with 2.5Transfection of HEK293 cells using Stemfect RNA
transfection reagent led to the highest transfection effi-
ciency, approximately 94% of cells expressed eGFP.
However, the eGFP expression in cells measured by
fluorescence intensity was lowest compared to the other
transfection reagents. The transfection efficiency using
TransIT mRNA transfection reagent and Lipofectamine
2000_optimized was similar with approximately 80%
eGFP expressing cells. The fluorescence intensity in
these cells was also not significantly different.
Using Stemfect RNA transfection reagent, about 74%
of the analyzed BJ fibroblasts were transfected with
mRNA. However, like in HEK293 cells, the protein
expression in the BJ fibroblasts was lowest after the
transfection with Stemfect RNA transfection reagent
compared to other transfection reagents. Lipofectamine
2000_optimized resulted in best transfection efficiency
with approximately 87% eGFP positive cells.
Very low amounts of ECs could be transfected using
Stemfect RNA transfection reagent and Lipofectamineμg eGFP mRNA using different amounts of Lipofectamine 2000.
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transfection using Trans-IT mRNA transfection reagent
or Lipofectamine 2000_optimized resulted in high trans-
fection efficiency. The eGFP expression in cells was not
significantly different after transfection with both trans-
fection reagents.
Transfection of cells with different Lipofectamine
2000 amounts
HEK293 cells, BJ fibroblasts, and ECs were transfected with
2.5 μg eGFP mRNA using 1, 2, 4, and 6 μl of Lipofectamine
2000 for generation of transfection complexes (Figure 3).
The percentage of eGFP expressing HEK293 cells was
not significantly different between the transfections with
different Lipofectamine 2000 amounts. Approximately 91%
of the cells were eGFP positive. However, the use of 2 μl Li-
pofectamine 2000 resulted in significantly higher fluores-
cence intensity (Geo Mean) in HEK293 cells than after the
transfection with 1 μl Lipofectamine 2000. The use of 4 μlFigure 4 Transfection of HEK293 cells, BJ fibroblasts, and ECs with 2Lipofectamine 2000 did not lead to significantly higher
fluorescence intensity than the transfection with 2 μl. After
the transfection with 2 μl Lipofectamine 2000, the Geo
Mean was approximately 710.
The transfection of BJ fibroblasts with different Lipofecta-
mine 2000 amounts did not result in significantly different
percentage of eGFP positive cells. Approximately 83% of
the cells were positive for eGFP expression. The use of 4 μl
Lipofectamine 2000 showed significantly higher Geo Mean
compared to the use of 1 μl Lipofectamine. Using 4 μl Lipo-
fectamine 2000, a Geo Mean of 210 was detected.
The performance of EC transfection with 6 μl Lipofecta-
mine 2000 led to decreased percentage of eGFP positive
cells compared to the transfection with 2 μl Lipofectamine
2000. The transfection with 1, 2, and 4 μl Lipofectamine
2000 resulted in approximately 87% eGFP positive cells.
The use of these different Lipofectamine 2000 amounts for
transfection showed no significant differences. Using 2 μl
Lipofectamine 2000, a Geo Mean of 362 was detected.μl Lipofectamine 2000 and different amounts of eGFP mRNA.
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The mRNA transfection complexes were generated by
using 2 μl Lipofectamine 2000 and different amounts of
eGFP mRNA, 0, 0.5, 1, 1.5, 2, and 2.5 μg. After the
transfection of HEK293 cells, BJ fibroblasts, and ECs,
the percentage of eGFP positive cells and the Geo Mean
was determined using flow cytometry (Figure 4).
Already the transfection of HEK293 cells with 0.5 μg
mRNA resulted in detection of 86% eGFP positive cells.
The increasing of the mRNA amount did not signifi-
cantly increase the percentage of transfected cells. But
the use of 1.5 μg mRNA led to higher eGFP expression
in cells than the use of 0.5 μg mRNA (Geo Mean of 590
versus 363). However, the transfection of cells with more
than 1.5 μg mRNA did not increase the eGFP expression
in the cells.
The transfection of BJ fibroblasts with 0.5 μg mRNA
led to the transfection of 75% of the cells. The increasing
of the mRNA amount did not result in significantlyFigure 5 Transfection of HEK293 cells, BJ fibroblasts, and ECs with eGhigher transfection efficiency. The transfection of 1.5 μg
mRNA led to significantly higher fluorescence intensity
than the negative cells. The Geo Mean was 239.
The use of only 0.5 μg mRNA led to the transfection
of 79% of all ECs. The transfection efficiency was not en-
hanced by increasing the mRNA amount. Already 0.5 μg
mRNA led to significantly higher expression of eGFP in
ECs than in the negative cells. The detected Geo Mean
was 262. The use of higher amounts of mRNA did not
lead to increased eGFP synthesis.
Determination of eGFP expression in mRNA transfected
cells over time
The duration of synthetic mRNA induced protein ex-
pression in HEK293 cells, BJ fibroblasts, and ECs was
determined after the transfection of cells with 2.5 μg
mRNA using 2 μl Lipofectamine 2000. The eGFP ex-
pression in cells was determined 1, 2, and 3 days after
transfection using flow cytometry (Figure 5).FP mRNA and determination of eGFP expression for 3 days.
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HEK293 cells showed a significant decrease of the por-
tion of eGFP producing cells after 3 days. However, after
3 days, 69% of analyzed cells were still positive for eGFP
expression. Over time, a continuous decrease of eGFP
expression in the cells was detected. After 3 days, the
detected Geo Mean was approximately 4 times less than
1 day after transfection.
The percentage of eGFP positive BJ fibroblasts did not
significantly change over time. But the eGFP expression
in the cells was 2 days post-transfection higher than
after 1 day. The fluorescence intensity of the cells did
not change after 3 days.
Approximately 88% of ECs were positive for eGFP ex-
pression and the amount of eGFP positive cells did not
change during 3 days. The eGFP expression peak was
measured 1 day post-transfection. A significant decrease
of Geo Mean was detected 2 days after transfection.
However, the detected fluorescence intensity did not
change in the following day.Fluorescence microscopic analysis of eGFP
transfected cells
HEK293 cells, BJ fibroblasts, and ECs were transfected
with 1.5 μg eGFP mRNA using 2 μl Lipofectamine 2000.
After 24 h, the eGFP expression in cells was investigated
by fluorescence microscopy (Figure 6). The analyses
demonstrated strongly fluorescent HEK293 cells. TheFigure 6 Fluorescence microscopic analyses of A) HEK293 cells, B) BJfluorescence intensity of BJ fibroblasts was weaker than
of the ECs.
Discussion
In recent years, the induction of protein expression in cells
by delivery of synthetic modified mRNA gained in import-
ance. Thereby, cells can be triggered to synthesize proteins
for treatment of diseases caused by inability of cells to pro-
duce a key protein. For example genetic disorders can be
corrected by introduction of mRNA that codes for the
missing or defective protein [13]. Furthermore, mRNA
therapeutics can also be used as vaccines to synthetize pro-
tein antigens for activation of the host immune system to
effectively eliminate tumor cells or prevent infections
[5,14]. Moreover, mRNA was also successfully used to re-
program finally differentiated somatic cells into pluripotent
stem cells by the expression of reprogramming factors [3].
In a recent study, MSCs were mRNA engineered to synthe-
tize increased amounts of proteins for enhanced regenera-
tive potential [15].
Here, modified eGFP mRNA was synthetized and the
mRNA transfection behavior of different cell types, pri-
mary cells such as ECs, BJ fibroblasts, and the HEK293
cell line, was analyzed. The determined optimal condi-
tions can be used to achieve maximal transfection effi-
ciency and expression of desired proteins especially in
ECs. But above all, we demonstrated the successful
transfection of ECs with synthetic mRNA, which re-
sulted in production of functional protein.fibroblasts, and C) ECs 24 h after eGFP mRNA transfection.
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fection conditions were determined. The transfection of
ECs with Stemfect RNA transfection reagent and Lipofecta-
mine 2000 in cell culture medium resulted in very low
levels of transfection. In contrast, transfection of cells with
Lipofectamine 2000/mRNA complexes in Opti-MEM I re-
duced serum media or the use of TransIT mRNA transfec-
tion reagent/mRNA complexes in cell culture medium led
to a high transfection efficiency between 80 and 90%. The
measurements also demonstrated that HEK293 cells can be
successfully transfected with high efficiency using TransIT
mRNA transfection reagent or Lipofectamine 2000_opti-
mized method. BJ fibroblasts showed highest transfection
efficiency using Lipofectamine 2000_optimized method.
The use of transfection reagents in low amounts can lead
to reduced transfection efficiency and on the other hand
when they are used in high amounts, they can induce cell
toxicity. Thus, the use of optimal mRNA to lipofectamine
ratio is important to maintain cell viability and high trans-
fection efficiency. The transfection of HEK293 cells, BJ fi-
broblasts, and ECs was performed with different amounts
of Lipofectamine 2000. The measurements showed that the
transfection of BJ fibroblasts can be performed using 4 μl
Lipofectamine 2000, for HEK293 cells 2 μl was sufficient
and the transfection of ECs can be performed with 1 or
2 μl Lipofectamine 2000. The use of 6 μl Lipofectamine
2000 for transfection of ECs resulted in decreased transfec-
tion efficiency, which indicates a toxic effect of Lipofecta-
mine 2000 in higher concentrations. This shows that the
Lipofectamine 2000 concentration should be optimized for
each cell type.
After the mRNA transfection, HEK293 cells showed
higher fluorescence intensities than ECs and BJ fibroblasts,
which means that they produce higher amounts of eGFP.
In comparison to ECs with a Geo Mean of 362 and BJ fi-
broblasts with a Geo Mean of 210, the Geo Mean of
HEK293 cells was 710. This was also confirmed by fluores-
cence microscopic analyses. However, despite different
fluorescence intensities, all cell types demonstrated a high
transfectability.
The transfection of cells already with 0.5 μg mRNA
and 2 μl Lipofectamine 2000 resulted in a high trans-
fection efficiency, 86% of HEK293 cells, 75% of BJ
fibroblasts, and 79% of ECs were eGFP positive. How-
ever, the increasing of mRNA amount from 0.5 μg to
1.5 μg led to significantly increased eGFP synthesis in
HEK293 cells. The transfection of BJ fibroblasts with
1.5 μg mRNA was needed to detect significantly
higher expression of eGFP in the cells compared to
the control cells. In contrast, the transfection of ECs
only with 0.5 μg eGFP mRNA was sufficient to
induce significantly increased protein expression com-
pared to the control cells. The expression did not
change by increasing the mRNA amount to 2.5 μg.Only after a single transfection with eGFP mRNA, all cell
types expressed eGFP for 3 days. Thus, these results
showed that by using synthetic modified mRNA the protein
expression can be maintained over a few days in transfected
cells. The eGFP expression reached the maximum on day 2
in BJ fibroblasts and showed no change on day 3. In ECs,
the eGFP expression was highest 1 day post-transfection
and decreased after 2 days. However, the detected fluores-
cence intensity after 3 days was still high with a Geo Mean
of approximately 470. Each day, the eGFP expression con-
tinuously decreased in HEK293 cells. These cells are rapidly
dividing cells with a doubling time of approximately 24 h.
Thus, the rapid decrease of the fluorescence intensity com-
pared to BJ fibroblasts and ECs could be caused by halving
of the eGFP amount after each division.
Conclusion
Here, we described the production of modified mRNA
for exogenous delivery into cells to induce protein ex-
pression. The delivery of the generated mRNA led to the
synthesis of eGFP in ECs, which was present during
3 days in the cells. However, the results also demon-
strated that the transfection method, reagent, and the
amount of mRNA and transfection reagent influence the
successful mRNA delivery and thus the expression of
the protein. Using the exogenous mRNA delivery, each
cell type could be induced to temporarily produce the
desired proteins. This method has great potential for
therapeutic applications, but each application has to be
first optimized individually.
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